Pipeline

August 12, 2019

Company	Drug/Device	Medical Condition	Status
Precigen, Inc.	PRGN-3005 UltraCAR-T	advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer	Phase 1 trial initiated
Soricimed Biopharma, Inc.	SOR-C13	late stage pancreatic cancer	Phase 1b trial initiated enrolling 36 subjects with advanced solid tumor cancers at The University of Texas MD Anderson Cancer Center (MDACC)
89Bio Ltd.	BIO89-100	nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) and high risk of NASH	Phase 1b/2a trial initiated enrolling 83 subjects
Provention Bio, Inc.	PRV-3279	lupus	Phase 1b/2a trial initiated enrolling 16 healthy volunteers
Eureka Therapeutics, Inc.	ET140202 ARTEMIS T-Cell therapy	advanced hepatocellular carcinoma (HCC) liver cancer	Phase 1/2 trial initiated enrolling subjects with metastatic or locally advanced, inoperable liver cancer and have progressed or have not been able to tolerate at least one line of treatment at City of Hope in Duarte, CA
RegeneRx Biopharmaceuticals, Inc.	RGN-137	epidermolysis bullosa (EB)	Phase 2 trial initiated
POXEL SA	PXL770	NASH	Phase 2a trial initiated enrolling 100 subjects with nonalcoholic fatty liver disease (NAFLD) who likely have NASH at sites in the U.S.
Altavant Sciences	rodatristat ethyl	pulmonary arterial hypertension (PAH)	Phase 2a trial initiated enrolling 36 subjects
Astellas Pharma, Inc.	fezolinetant	moderate-to-severe vasomotor symptoms (VMS)	Phase 3 trial initiated enrolling 450 subjects at 20 sites in the U.S., Canada and Europe
Apyx Medical Corporation	next-generation J-Plasma Precise Handpiece	open and laparoscopic surgical procedures	510(k) clearance granted by the FDA
Alnylam Pharmaceuticals, Inc.	givosiran	acute hepatic porphyria (AHP)	Priority Review granted by the FDA
Provention Bio, Inc.	teplizumab (PRV-031)	prevention or delay of clinical type 1 diabetes (T1D) in at-risk individuals	Breakthrough Therapy designation granted by the FDA
Inotrem S.A.	nangibotide (LR12)	septic shock	IND approval granted by the FDA
Daiichi Sankyo	Turalio (pexidartinib) capsules	subjects with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery	Approval granted by the FDA
Bracco Diagnostics, Inc.	VARIBAR THIN LIQUID (barium sulfate) for oral suspension	dysphagia	Approval granted by the FDA